Top Back to top

Phase 2 trial to assess haploidentical a/ß T-depleted stem cell transplantation in patients with sickle cell disease with no available sibling donor (T-Haplo-HSCT for SCD)

Study number:
Eudra-CT 2018-002652-33
Short title:
T-Haplo-HSCT for SCD
Study status:
Beginning of enrollment expected in fourth quarter 2019
Deadline for data collection:
Study design:
Prospective, multicenter, interventional phase 2 trial
Primary objective:
Primary efficacy endpoint: Composite Endpoint: Event free survival (EFS). Event is defined as incidence of acute GvHD (Grade II – IV), chronic GvHD (moderate/severe), graft failure (GF), or death (from any reason).
Key secondary endpoint(s): (i) Overall survival (OS); (ii) Disease-free survival (DFS); (iii) Graft failure (GF); (iv) immune-reconstitution; (v) Quality of life (QOL); (vi) Fertility
Key inclusion criteria:
• Age 1yr to 35yrs
• Homozygous hemoglobin S disease or heterozygous hemoglobin SC or S 0/+
• Preexisting severe or moderate SCD related complications:
o Clinically significant neurological event (stroke) or deficit >24h o Silent crisis,
neurocognitive deficit, pathological Angio-MRI with TOF Sequence
o A TCD velocity >200cm/s at 2 occasions >1 month apart
o More than five vaso-occlusive crises (VOC) in the past 1 year
o Two or more episodes of acute chest syndrome (ACS) in their lifetime or one episode of
ACS in the past 24 months
o Receiving chronic, monthly blood transfusions
o Transfusion-refractory allo-immunization
o More than five VOC in a lifetime
o More than five SCD-related hospitalizations in a lifetime
o More than eight transfusions or one exchange transfusion
o Beginning pulmonary hypertension
o Osteonecrosis at more than 2 sites
o Beginning SCD Nephropathy
Principal investigator:
Selim Corbacioglu
Principal investigator email:
EBMT Study coordinator:
Arnaud Dalissier
Study coordinator email:

Need help?

The personal data provided will be processed according to the General Data Protection Regulation (GDPR 2016/679 ) and incorporated to a file property of EBMT which will be allocated in the EEA (European Economic Area) or in countries that are provided with the same level of protection for privacy such as countries that adhere to EU-US and Swiss-US Privacy Shield Frameworks.
Data Subjects have the right of access to his or her data and the right to rectification of any inaccurate or incomplete personal data. The Data Subject also has the right to withdraw consent, this wish will be respected, and the personal will no longer be made available. If the processing operation is unlawful the Data Subject has the right to request deletion of that data. Please write to